Viridian Therapeutics

VRDN · NASDAQ

$22.43+$1.63 (+7.84%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $20.80

VRDN analyst rating

BuyConsensus of 12 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy12
Hold0
Underperform0
Sell0

12-month price target · 17 analysts

Average $36.92 (+64.6% upside)

Low: $22.22
Now: $22.43
High: $52.50

Upgrades and downgrades

The latest rating actions, newest first

VRDN analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
RBC Capital	Sep 22, 2026	Maintains	Outperform	$36.00 → $38.00	44%
RBC Capital	Aug 7, 2026	Maintains	Outperform	$35.00 → $36.00	44%
Truist Securities	Aug 7, 2026	Maintains	Buy	$38.00 → $39.00	47%
RBC Capital	Jun 30, 2026	Maintains	Outperform	$34.00 → $35.00	44%
Truist Securities	Jun 30, 2026	Maintains	Buy	$35.00 → $38.00	47%
Wedbush	Jun 30, 2026	Maintains	Outperform	$32.00 → $43.00	40%
Needham	Jun 30, 2026	Maintains	Buy	$32.00 → $34.00	53%
Wells Fargo	Jun 29, 2026	Upgrade	Equal-Weight → Overweight	$20.00 → $31.00	54%
Needham	Jun 29, 2026	Maintains	Buy	$32.00	53%
Evercore ISI Group	May 15, 2026	Maintains	Outperform	$27.00 → $26.00	43%

The case for and against

Updated Oct 21, 2026

Bull case

Viridian Therapeutics is supported by a differentiated IGF-1R platform that has shown marked improvement in proptosis, diplopia, and CAS versus teprotumumab, with management and KOLs viewing veligrotug as a best-in-class option for active and chronic TED. Early Lumvoa launch data are encouraging, with 95% of the ~2,000 core prescribers contacted, first doses administered in July, and multiple KOLs already writing prescriptions, while payer friction appears manageable and could improve further with a permanent J-code expected in 1Q27. The opportunity is reinforced by a large, underpenetrated TED market, where Tepezza generated $576m in Q2 and chronic TED remains less than 5% treated, while elegant subcutaneous options and a broader pipeline add longer-term growth optionality.

Bear case

Viridian Therapeutics is a high-risk, single-asset-driven story whose lead TED programs must overcome regulatory and safety uncertainty while facing an entrenched competitor, Tepezza, with a 6-7 year head start and the backing of Amgen’s resources. The KOL feedback points to real commercial friction: active TED patients are only 10–25% of TED volume, anti-IGF-1R use is constrained by hearing-loss fears, recurrence concerns, and inconsistent prescribing, with utilization ranging from 50% to 10% and some doctors sharply reducing use. Financially, the company is still burning cash as a clinical-stage biopharma, posting 2Q26 R&D of $72m, SG&A of $55m, and a net loss of $127m, while management may need additional capital and a failure of veligrotug could leave the stock near net cash value.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.